Skip to main content

Progress Made Toward NASH Diagnosis and Drug Discovery

 A buildup of fat in the liver could cause an aggressive type of nonalcoholic fatty liver disease (NAFLD), called nonalcoholic steatohepatitis (NASH) which is a condition with liver inflammation and damage. Most of the time, it causes no symptoms and no problems, while in some worse cases, the fat causes inflammation and damages liver cells, affecting the normal function of the liver or even leading to cirrhosis. Though the second leading indication for liver transplantation in the United States, NASH has no FDA-approved treatments currently. This is drawing concerns from all stakeholders, including patients and providers, for which experts call for a great deal of focus on understanding and addressing this important liver disease that impacts clinical outcomes and the quality of life.

 

Diagnosis of NASH

 

Because NASH are asymptomatic until patients are identified at advanced stages, a liver biopsy remains the gold standard for making early predictive and definitive NASH diagnosis and staging. However, the liver biopsy is an invasive procedure that has several drawbacks, including sampling error, high expense, side effects like pain and bleeding, and the impracticability of performing liver biopsies on all NASH patients. All these unfavorable factors are prompting the technology for developing reliable, precise, and noninvasive NASH diagnostic approaches.

 

Biomarkers, as noninvasive and reliable alternatives to liver biopsy, contribute to the early diagnosis of NASH by indicating biological characteristics in a normal or pathologic process. Conventional NASH biomarkers like liver enzymes have different drawbacks. And currently, it's not possible to identify fibrosis and steatosis, to early diagnose NASH, or to predict the disease progression with one biomarker alone single test. There are many novel noninvasive tests are in development, and multi-omics biomarkers, including those focusing on microbiota, seem to be promising if only combinatorial methods were standardized and implemented.

 

Treatment of NASH

 

Though no pharmacologic therapy has been approved to treat NASH and clinical advice on treating this disease is more about lifestyle modification based on body weight and exercise, the NASH therapeutic pipeline is robust.

 

As a matter of fact, there are approximately dozens of projects for NASH drug development with different mechanisms. They are being investigated in various phases of drug development, some of which undoubtedly would come across setbacks but numerous drugs still are showing great promise for the potential to treat NASH. With different endpoints like a histological improvement, NASH resolution, prevention of progression to cirrhosis, and fibrosis stage regression, some NASH drugs are expected to be approved on the basis of relatively short-term studies. However, it's also pointed out that in the race of developing medical treatment of NASH, lifestyle modification is still the most effective treatment currently available for NASH patients.

 

Researchers have a positive attitude toward the future of NASH drug approval and look forward to receiving approval for at least one additional serum biomarker in recent years. Also, as NASH is a complex and multiorgan disease involving different mechanisms of action, experts indicated that it would be beneficial to have several approved drugs to tailor different treatments for different patients.

 

Labels:

Comments

Post a Comment

Popular posts from this blog

Everything You Want to Know About Antibody Development

  Everything You Want to Know About Antibody Development   When foreign molecules, which are known as antigens, enter our body, antibodies will be released by B cells of the immune system to specifically bind to the antigens and finally clear out those “invaders”. Such a highly specific molecular recognition mechanism has inspired a variety of antibody development research and diagnostic applications nowadays, including IVD antibody development .   What is Antibody Development?   Antibody development is the process of creating and characterizing an antibody.   The timeline of developing antibodies starts from the injection of an antigen of interest into a host animal, so that the host’s immune system can detect it and generat e  the desired antibodies. Then, antibody development proceeds with finding and isolating the desired antibodies from the rest of the protein in sera.   The reset procedure of antibody development is varied as the desired antibodi...
Post a Comment
Read more

An Overview of the Global Bispecific Antibody Therapeutics Market

  Antibod ies , a major component of adaptive immunity, play a critical role in protective and pathogenic immune responses. In r ecent years, a wide range of antibodies is discovered as candidates of cancer therapeutic agents, including the reconstructive molecules, bispecific antibodies (BsAbs).   About Bispecific Antibody   Bispecific antibodies, as its name indicates, consists of two antigen-binding sites, which can simultaneously bind two separate and unique antigens (or different epitopes of the same antigen). This structure is  typically designed to bind to two targets, one on a cancer cell and one on an immune cell, act ivating or redirecting immune effector cells with the goal of getting the immune cell to kill the cancer cell by antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) and other cytotoxic mechanisms.   U nique biological and pharmacological properties, ...
Post a Comment
Read more

Unmodified Bacteriophages Research Updates

  R ecent research conducted by researchers from Yale University is published in  Applied and Environmental Microbiology , suggesting  that natural bacteriophage, or phage, can kill dysentery-causing bacteria and reduce virulence in surviving bacteria. It's a piece   of  inspiring news as  treating dysentery has become a challenge with the rising antibiotic resistance.   Background   Shigella flexneri , the culprit causing contagious infection marked by inflammatory diarrhea and dysentery in sub-Saharan Africa and southern Asia, kills about 160,000 people globally every year. The World Health Organization (WHO) takes priority to this pathogen in terms of increasing cases, antimicrobial resistance, and limited treatment options.   S. flexneri  is active primarily in low-income countries, like southern Asia and sub-Saharan Africa. In these places, dirty drinking water is a concern causing dysentery, while antibiotics are expensive and unav...
Post a Comment
Read more